DK2037950T3 - Yderligere medicinske anvendelser af antisekretorisk protein - Google Patents
Yderligere medicinske anvendelser af antisekretorisk proteinInfo
- Publication number
- DK2037950T3 DK2037950T3 DK07748080.4T DK07748080T DK2037950T3 DK 2037950 T3 DK2037950 T3 DK 2037950T3 DK 07748080 T DK07748080 T DK 07748080T DK 2037950 T3 DK2037950 T3 DK 2037950T3
- Authority
- DK
- Denmark
- Prior art keywords
- tumour
- medical applications
- treatment
- further medical
- antisecretory
- Prior art date
Links
- 230000001262 anti-secretory effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108010038288 antisecretory factor Proteins 0.000 abstract 2
- 206010010121 compartment syndrome Diseases 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000001126 phototherapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Marine Sciences & Fisheries (AREA)
- Dispersion Chemistry (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0600933 | 2006-04-27 | ||
| US92082607P | 2007-03-30 | 2007-03-30 | |
| PCT/SE2007/000415 WO2007126365A2 (en) | 2006-04-27 | 2007-04-27 | Further medical uses of antisecretory protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2037950T3 true DK2037950T3 (da) | 2014-06-30 |
Family
ID=38655929
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07748080.4T DK2037950T3 (da) | 2006-04-27 | 2007-04-27 | Yderligere medicinske anvendelser af antisekretorisk protein |
| DK10188590.3T DK2363140T3 (en) | 2006-04-27 | 2007-04-27 | ANTI-SECRETORIC PROTEIN TO USE IN THE TREATMENT OF COMPARTMENT SYNDROME |
| DK07748078.8T DK2040734T3 (da) | 2006-04-27 | 2007-04-27 | Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10188590.3T DK2363140T3 (en) | 2006-04-27 | 2007-04-27 | ANTI-SECRETORIC PROTEIN TO USE IN THE TREATMENT OF COMPARTMENT SYNDROME |
| DK07748078.8T DK2040734T3 (da) | 2006-04-27 | 2007-04-27 | Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8309513B2 (enExample) |
| EP (2) | EP2363140B1 (enExample) |
| JP (2) | JP5323682B2 (enExample) |
| KR (3) | KR101805973B1 (enExample) |
| CN (3) | CN101437533B (enExample) |
| AT (1) | ATE526031T1 (enExample) |
| AU (1) | AU2007244003B2 (enExample) |
| BR (2) | BRPI0710858A2 (enExample) |
| CA (1) | CA2650589C (enExample) |
| DK (3) | DK2037950T3 (enExample) |
| ES (3) | ES2374712T3 (enExample) |
| IL (1) | IL194774A (enExample) |
| MX (1) | MX2008013774A (enExample) |
| NZ (2) | NZ572256A (enExample) |
| PL (2) | PL2040734T3 (enExample) |
| RU (2) | RU2465914C2 (enExample) |
| SG (1) | SG171601A1 (enExample) |
| WO (1) | WO2007126363A2 (enExample) |
| ZA (2) | ZA200809116B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008013769A (es) * | 2006-04-27 | 2009-02-03 | Lantmaennen As Faktor Ab | Uso de factores antisecretores para el tratamiento de hipertension intraocular. |
| AU2007244005B2 (en) * | 2006-04-27 | 2012-08-02 | Lantmannen As-Faktor Ab | Further medical uses of antisecretory protein |
| CN101437533B (zh) | 2006-04-27 | 2016-10-12 | 兰特门内阿斯-法克托尔公司 | 抗分泌蛋白对于治疗间室综合症的应用 |
| US9220750B2 (en) * | 2007-04-27 | 2015-12-29 | Lantmannen As-Faktor Ab | Use of antisecretory factors (AF) for optimizing cellular uptake |
| US9962424B2 (en) | 2007-04-27 | 2018-05-08 | Lantmännen As-Faktor Ab | Use of antisecretory factors (AF) for optimizing cellular uptake |
| US8901083B2 (en) | 2008-11-25 | 2014-12-02 | Temple University | Administration of angiocidin for the treatment of leukemia |
| WO2017009004A1 (en) | 2015-07-10 | 2017-01-19 | Lantmännen As-Faktor Ab | Process for producing egg yolk with high content of af-16 |
| US11407796B2 (en) | 2016-07-18 | 2022-08-09 | Lantmännen As-Faktor Ab | Antisecretory factor 17 |
| CA3103164A1 (en) * | 2018-06-28 | 2020-01-02 | Lantmannen Medical Ab | Antisecretory factor for use in treatment and/or prevention of acute respiratory failure |
| CN112770644A (zh) | 2018-09-28 | 2021-05-07 | 兰特门内保健食品公司 | 包含麦芽化小麦的可消耗产品 |
| CN112770643A (zh) | 2018-09-28 | 2021-05-07 | 兰特门内保健食品公司 | 包含麦芽化脱壳燕麦的可消耗产品 |
| JP2023518790A (ja) | 2020-03-26 | 2023-05-08 | ラントメネン・ファンクショナル・フーズ・アーベー | 身体活動時の回復を促進するための麦芽穀類を含む消費可能な製品 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH682716A5 (de) * | 1992-01-13 | 1993-11-15 | Christian Fricker | Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung. |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| SE508609C2 (sv) | 1995-08-24 | 1998-10-19 | Rural Patent Svenska Ab | Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning |
| SE506486C2 (sv) | 1996-11-20 | 1997-12-22 | Svenska Lantmaennen Riksfoerbu | Födoämne som vid förtäring inducerar antisekretoriska proteiner |
| SE513496C2 (sv) | 1998-12-17 | 2000-09-18 | Rural Patent Svenska Ab | NASP-berikad äggula samt dess användning |
| US7662169B2 (en) * | 2000-09-05 | 2010-02-16 | Wittmann Dietmar H | Prosthesis and method for lowering abdominal pressure |
| GB0322645D0 (en) | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| AU2007244005B2 (en) | 2006-04-27 | 2012-08-02 | Lantmannen As-Faktor Ab | Further medical uses of antisecretory protein |
| CN101437533B (zh) | 2006-04-27 | 2016-10-12 | 兰特门内阿斯-法克托尔公司 | 抗分泌蛋白对于治疗间室综合症的应用 |
| WO2009052478A1 (en) * | 2007-10-19 | 2009-04-23 | Trustees Of Boston University | Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide |
-
2007
- 2007-04-27 CN CN200780014998.9A patent/CN101437533B/zh active Active
- 2007-04-27 KR KR1020147032781A patent/KR101805973B1/ko not_active Expired - Fee Related
- 2007-04-27 ES ES07748078T patent/ES2374712T3/es active Active
- 2007-04-27 ES ES10188590.3T patent/ES2615515T3/es active Active
- 2007-04-27 MX MX2008013774A patent/MX2008013774A/es active IP Right Grant
- 2007-04-27 SG SG201102875-0A patent/SG171601A1/en unknown
- 2007-04-27 DK DK07748080.4T patent/DK2037950T3/da active
- 2007-04-27 AT AT07748078T patent/ATE526031T1/de not_active IP Right Cessation
- 2007-04-27 ES ES07748080.4T patent/ES2472737T3/es active Active
- 2007-04-27 CN CN200780014997.4A patent/CN101460187B/zh not_active Expired - Fee Related
- 2007-04-27 KR KR1020147027241A patent/KR101757523B1/ko active Active
- 2007-04-27 JP JP2009507631A patent/JP5323682B2/ja active Active
- 2007-04-27 AU AU2007244003A patent/AU2007244003B2/en active Active
- 2007-04-27 CN CN201510082714.6A patent/CN104689299B/zh active Active
- 2007-04-27 NZ NZ572256A patent/NZ572256A/en not_active IP Right Cessation
- 2007-04-27 BR BRPI0710858-3A patent/BRPI0710858A2/pt not_active Application Discontinuation
- 2007-04-27 CA CA2650589A patent/CA2650589C/en active Active
- 2007-04-27 DK DK10188590.3T patent/DK2363140T3/en active
- 2007-04-27 NZ NZ572257A patent/NZ572257A/en not_active IP Right Cessation
- 2007-04-27 KR KR1020087029120A patent/KR20090045148A/ko not_active Ceased
- 2007-04-27 RU RU2008146734/15A patent/RU2465914C2/ru active
- 2007-04-27 BR BRPI0710794-3A patent/BRPI0710794A2/pt not_active IP Right Cessation
- 2007-04-27 WO PCT/SE2007/000413 patent/WO2007126363A2/en not_active Ceased
- 2007-04-27 DK DK07748078.8T patent/DK2040734T3/da active
- 2007-04-27 RU RU2008146731/15A patent/RU2457853C2/ru active
- 2007-04-27 EP EP10188590.3A patent/EP2363140B1/en active Active
- 2007-04-27 PL PL07748078T patent/PL2040734T3/pl unknown
- 2007-04-27 EP EP07748078A patent/EP2040734B1/en active Active
- 2007-04-27 PL PL10188590T patent/PL2363140T3/pl unknown
-
2008
- 2008-10-22 IL IL194774A patent/IL194774A/en active IP Right Grant
- 2008-10-23 ZA ZA200809116A patent/ZA200809116B/xx unknown
- 2008-10-23 ZA ZA200809114A patent/ZA200809114B/xx unknown
- 2008-10-27 US US12/289,389 patent/US8309513B2/en active Active
-
2010
- 2010-11-02 JP JP2010245989A patent/JP5285043B2/ja active Active
-
2011
- 2011-02-11 US US13/025,702 patent/US8389468B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2040734T3 (da) | Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1121735T1 (el) | 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου | |
| CR9312A (es) | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| CY1111065T1 (el) | Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| BR112019021822A2 (pt) | Terapia de combinação | |
| DK2305255T3 (da) | Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| NO20053782L (no) | Behandling av kreft med 2-deoksyglukose | |
| EA201290356A1 (ru) | Композиции для лечения тошноты и рвоты центрального происхождения | |
| CU24046B1 (es) | Compuestos peptídicos que inhiben el virus de la hepatitis c | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| CY1117394T1 (el) | Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορων | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| ATE511889T1 (de) | Partikeltherapieanlage | |
| EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| JP2009530288A5 (enExample) | ||
| CO6531463A2 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
| NO20084749L (no) | Organiske forbindelser og deres anvendelser | |
| NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
| CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| EA200901080A1 (ru) | Новые нуклеозидные аналоги для лечения вирусных инфекций | |
| EA201170484A1 (ru) | Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950 |